Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow again...!
Oats, nailed this sucker...
Don't know. They have some competition as Aurora is 4 blocks away.
I'm curious about that.
Billy, you work for Home Depot?
Oats, this is one of the most active stocks that came
to bloom. I said it once and i'll say it again,
this is a "ALMAZ" (Russian for a diamond in the rough.)
Brandao, Supreme is 4 blocks away from this co. I own both, so really not
sure who's going to win the race. Aurora has the price edge now, but Supreme is also an outstanding co. What's your take?
Up .12 as of 3:30pm... Not a bad rebound. Tomorrow someone will yell "the sky is falling" and back to the 1.80s..
FYI
InMed's Cannabis Pipeline, Financials and Prospects
Accesswire AccesswireFebruary 16, 2017
NEW YORK, NY / ACCESSWIRE / February 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is covering InMed Pharmaceuticals Inc. (IMLFF). During 2016, ImMed achieved some significant milestones, including: induction of strong biopharmaceutical expertise in their senior management team, financial closures to fund continued drug/disease target identification, advanced analysis of existing datasets to ensure clinical development plans are accurate and positioned to maximize the likelihood for positive outcomes, validation and advancement of the manufacturing process, filing of provisional patents, and expanded scope of opportunities for cannabinoid-based products.
The company continues to focus on research into fundamental benefits of cannabinoid drugs to address high unmet medical needs, selective advancement of high-potential drug candidates, identification and retention of industry veterans to define and execute the present & future drug development programs in a time- and cost-effective manner, collaboration with biotech-savvy investor groups & exploration into the partnership potential of the various programs and assets.
This is pure manipulation. Catch'em and hang them high! Don't walk up my path!
I'm in Maine, "shoot first ask questions later."
WOW!!!!!!!!!!$2.00 is in reach today or tomorrow...
I see no news so what's making this move?
Could be private investors seeing the light at the end of the tunnel.
FYI Motley Fool
2 Billion-Dollar Marijuana Stocks That Could Soar Even Higher
GW Pharmaceuticals and Canopy Growth Corporation belong to a rare breed: marijuana stocks with market caps of $1 billion or more that could grow even more.
Keith Speights (TMFFishBiz) Feb 12, 2017 at 11:01AM
You could have made plenty of money investing in the right marijuana stocks last year. Most, however, are small companies without much of a track record. Investing in these stocks is highly speculative, to say the least.
A few of these companies, though, have grown large enough to reach market caps of $1 billion or more. GW Pharmaceuticals (NASDAQ:GWPH) claims a market cap of nearly $3 billion, while Canopy Growth Corporation's (NASDAQOTH:TWMJF) stands right at $1 billion. Here's why these two billion-dollar marijuana stocks could soar even higher in 2017.
Marijuana bud against blurred background of money
IMAGE SOURCE: GETTY IMAGES.
Enthusiastic about Epidiolex
One press release was all it took to catapult GW Pharmaceuticals' market cap above the magic billion-dollar mark. On March 14, 2016, the biotech announced great results from its first late-stage clinical study of its lead cannabinoid drug Epidiolex in treating Dravet syndrome. Children with the severe form of epilepsy in the study who took Epidiolex were much less likely to experience convulsive seizures than were children on placebo.
That was just the beginning for GW Pharmaceuticals. The company announced results from another late-stage study in June, this time for Epidiolex in treating Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. GW's cannabinoid drug again helped dramatically reduce seizures.
Results from a second study of Epidiolex in treating LGS caused GW Pharmaceuticals' market cap to jump above $3 billion. Those results, announced in September, showed significant reduction in seizures for children taking a low dose of the drug (10 mg/kg/day) and a higher dose (20 mg/kg/day).
Based on these three successful clinical studies, GW Pharmaceuticals is moving forward with filing for regulatory approval of Epidiolex in the United States. The company expects to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2017.
Winning FDA approval would no doubt send GW Pharmaceuticals' shares even higher. Assuming the company does obtain that approval, the U.S. commercial launch for Epidiolex should come sometime in 2018. GW will have to wait on scheduling of the drug by the U.S. Drug Enforcement Agency before marketing Epidiolex. The company hopes Epidiolex will be placed into Schedule 4, which applies to all drugs with low potential for abuse and low risk of dependence.
Rapping presence
Canopy Growth Corporation is one of the largest providers of medical marijuana in Canada. The company is best known for its Tweed brand of marijuana. For most of last year, Canopy Growth's market cap hovered around the $300 million level.
That changed on Oct. 6, 2016, when the company announced the Canadian commercial launch of the Leafs by Snoop marijuana brand with famous rapper Snoop Dogg. Canopy Growth's market cap surged over the next couple of months, surpassing $1 billion by the middle of November. Since then, the stock has given up some of its gains. The company's valuation is just below $1 billion.
Canopy Growth first forged a deal with Snoop Dogg in February 2016. Snoop's company, LBC Holdings, received cash, royalties, and shares of Canopy Growth as part of the deal. The Leafs by Snoop brand was already on the market in Colorado, but the agreement allowed Canopy Growth to bring it to the Canadian market for the first time.
The Canadian government currently requires authorization by a healthcare practitioner for a person to legally obtain marijuana. Canopy Growth is one of several companies licensed by the government to provide medical marijuana.
However, Canada could potentially legalize marijuana in the coming months. Should restrictions on marijuana be lifted, Canopy Growth's partnership with Snoop Dogg could give it a leg up in gaining market share.
Big risks
GW Pharmaceuticals and Canopy Growth Corporation carry some of the largest market caps among marijuana stocks, but they're not without significant risks. For GW Pharmaceuticals, the first hurdle to overcome is winning FDA approval. Assuming the company gains that approval, it must successfully launch Epidiolex, including persuading payers to cover the drug.
For Canopy Growth, the primary risk is that the Canadian government chooses against legalization of marijuana. Even if laws are changed, there's always a risk that other competitors will be more successful.
Probably the biggest risk for both of these marijuana stocks, though, is that their valuation becomes greater than their financial prospects warrant. This problem isn't as great for GW Pharmaceuticals, in my view. I think Epidiolex, if approved, could generate peak annual sales of at least $1 billion -- enough to easily justify GW's stock going higher than current levels.
Canopy Growth, on the other hand, made less than $12 million in revenue in the six months ending Sept. 30, 2016. Even if we assumed tremendous sales growth this year, a market cap near $1 billion is tough to defend for this stock.
That doesn't mean Canopy Growth's shares won't go higher. I wouldn't be surprised if they did. However, what goes up can (and often does) fall down.
FYI
Marapharm Ventures Inc. "Marapharm" Announces That its Subsidiary, Marapharm Washington, LLC "Marapharm WA" has Entered Into an Agreement to Purchase 13.6 Acres of Industrial Land and Buildings Located in Washington State
PR Newswire PR NewswireFebruary 12, 2017
KELOWNA, British Columbia, February 13, 2017 /PRNewswire/ --
Marapharm Ventures Inc. (MRPHF) subsidiary, Marapharm WA has entered into an agreement to purchase 13.6 acres of industrial, highway frontage property located a few minutes south of the Canadian border for $4.2 million US. The transaction should close on or before February 28, 2017.
Previously, on June 16, 2016, the Company announced that it had concluded a deal for a lease of a 30,000 square foot building and an option to purchase 13.6 acres of industrial property located in Whatcom County, Washington State. Further, on August 17, 2016, Marapharm announced that Marapharm WA had closed on the purchase of the assets of a 30,000 square foot operating tier 3 marijuana cultivation and processing facility, located in Washington State and on September 27, 2016 and November 1, 2016 provided updates with regard to the Washington operations. Marapharm has been making lease payments on the property and has chosen to act on the option to purchase the land.
The 13.6 acres is appropriately zoned for Washington States I-502 marijuana cultivation and processing requirements. There are currently multiple buildings on the property, including the 30,000 square foot building with marijuana cultivation and processing licenses, a 9,190 square foot truck wash building, a 7,200 square foot mechanic shop, a 2208 square foot office building and large sheds. Wal-Mart presently uses an area of the property for truck and trailer parking. There is ample room for further development.
To view the property, go to http://www.marapharm.com and look at the images under Marapharm Washington.
"Marapharm WA plans to develop the property for cultivation, processing and research purposes, with the intention of creating a Cannabis Campus. We will continue to renovate the buildings which are presently in use, as well as, develop and build new structures as required. Since legalization, sales of marijuana products in Washington are more than $1 billion and taxes for the State are more than $250 million. This is a booming sector."Linda Sampson, Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
http://www.marapharm.com
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com) and Sedar website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
FYI
TSXV: ACB
VANCOUVER , Feb. 13, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (ACB.V) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and Radient Technologies ("Radient") (RTI.V) are pleased to provide an update on their previously announced collaboration arrangements.
Project Update
As previously announced, the parties have entered into a memorandum of understanding ("MOU") to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts.
In accordance with the memorandum of understanding ("MOU"), the parties, on January 4, 2017 , entered into a joint venture research agreement pursuant to which Radient and Aurora are working to confirm the effectiveness of Radient's MAPTM technology for cannabis extraction. Initial results from the first phase of the study are encouraging. As a result, the parties have agreed to move to the second phase of the project, which includes preliminary scale-up activities. The second phase of work under the study has commenced and is expected to take approximately eight weeks.
"We are pleased with progress to date in assessing the feasibility of this potentially ground breaking extraction technology," said Terry Booth , CEO. "The potential to substantially increase our extracts production capacity while maintaining terpene profiles would further differentiate our Company, and we are excited to be exploring this opportunity further in the coming weeks."
Convertible Debenture
Aurora and Radient are also pleased to announce that Aurora has completed its investment in the Radient convertible debenture, announced initially on December 14, 2016 (the "Debenture"). The Debenture will have a principal amount of $2 million , a term of 2 years, bear interest at 10% per annum, and will be convertible into units of Radient at a conversion price of $0.14 per Unit. Each Unit will be comprised of one common share of Radient and one share warrant, exercisable within 24 months, for one common share of Radient at an exercise price of $0.33 per warrant. The Debenture will be repayable on demand from Aurora at any point within five months from the date of issuance.
Radient Private Placement
Additionally, Aurora intends to participate as lead investor in the private placement announced today by Radient. The Company intends to invest up to $1.25 million in the offering. Units in the offering, priced at $0.45 each, are comprised of one common share of Radient and one half common share purchase warrant at a price of $0.70 per common share.
Denis Taschuk , President and CEO of Radient, stated "We are very encouraged with the initial positive results generated through the collective efforts of the Aurora and Radient teams, using our extraction expertise and technology for cannabis extraction, and we feel confident in meeting Aurora's objectives. Additionally, the increasing corporate ties between Aurora and Radient and the funds raised provide us both with the resources and the ideal platform to implement our go to market strategy."
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , and is currently constructing a second 800,000 square foot, highly automated production facility at the Edmonton International Airport. Aurora trades on the TSX Venture Exchange under the symbol "ACB".
About Radient
Radient extracts natural compounds from a range of biological materials using its proprietary MAPTM natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta , Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.
Something is up. Up in The Boston area getting hammered by the same storm!
Would like to see this hit 1.66 today. Still no recent news..
Something is up. Up in The Boston area getting hammered by the same storm!
Would like to see this hit 1.66 today. Still no recent news..
Oats, we're on the move again!!!
We're on the move again!
No news from what i can see, but the interview on HighNY was
impressive. I say $5.00 by the end of the year. I'm sure news
is on the way.
.09 today!!! somethings is up!
It's my understanding that there is a limited # of growers, pharmaceutical companies, processing companies etc.(40) (guessing) (that will be aloud by the Canadian Federal Gov.) which will to allow monitoring, and allow them to pull the reins in tight when needed. That's how it's starting and it will continue, (ie; OGRMF). If Canada establishes the ethics code of all who must play by, it's a gimme.
Looks like their going international. See what happens as Europe and the rest of the world climb aboard.
GO PATS!
It's my understanding that there is a limited # of growers, pharmaceutical companies, processing companies etc.(40) (guessing) (that will be aloud by the Canadian Federal Gov.) which will to allow monitoring, and allow them to pull the reins in tight when needed. That's how it's starting and it will continue, (ie; OGRMF). If Canada establishes the ethics code of all who must play by, it's a gimme.
Looks like their going international. See what happens as Europe and the rest of the world climb aboard.
GO PATS!
Thanks GB for the response.
Does anyone know when Mettrum shares will be converted to
WEED shares?
TY.
FYI
Marapharm Ventures Inc. Provides an Update of Its Investment Strategy with Veritas Pharma Inc.
PR Newswire PR NewswireFebruary 1, 2017
KELOWNA, British Columbia, February 1, 2017 /PRNewswire/ --
Marapharm Ventures Inc. (MRPHF). Marapharm's focus is on corporate growth and excellence by acquisitions, operations and investments. Marapharm invested in Veritas Pharma Inc. "Veritas" (news releases January 9 and January 11, 2017, Marapharm purchased 15 million shares and rights to acquire shares) and to date, this investment has increased substantially in value. The synergy with Veritas and Marapharm and the development of both company's products enhances corporate and shareholder value overall. Medical research by Veritas scientists can help to monetize Marapharm's intellectual properties and products of subsidiaries currently under development. Marapharm, with the assistance of Veritas, intends to advance its cannabis strains. "With our unique vertical grow system, yields and quality will be maximized. We think Veritas is a great business model and investment in the cannabis space. Marapharm is the majority owner and largest shareholder of Veritas," Linda Sampson, Marapharm CEO.
Veritas and or its subsidiary Cannevert Therapeutics Ltd. "Veritas"" have designed and are implementing clinical trials of cannabis strains for pain. Health Canada has granted permission to conduct research. Chemical and animal studies by Veritas have identified suitable strains that warrant immediate human trials which are intended to be implemented this year. The management team consists of veteran academic pharmacologists, anaesthetists and chemists whose commercial mission is to patent its findings in order to sell or license to cancer clinics and pharmaceutical companies, thereby, targeting multi-billion dollar global markets.
Well, lets see what happens to the PPS!
My bad. I apologize. Take it to the limit please!!
From what i see in the pps, things don't look that promising.
We don't see the whole story, because Mettrum could have issues as well as
Canopy. We all want POSITIVE news but maybe things aren't what they seem. I hold several shares and want the same thing you do, but not all that glitters is gold.
The Most Powerful Plant on Earth? | The Hemp Conspiracy | Documentary
FYI
Canopy Growth Corp. breached its 50 day moving average in a Bullish Manner : TWMJF-US : January 24, 2017
Edge, no problem...kinda figured that. Yes this is good news!
FYI
Organigram Reports Postive Cash Flow and Update on Recent Events
Marketwired MarketwiredJanuary 24, 2017
MONCTON, NEW BRUNSWICK--(Marketwired - Jan 24, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI) (OGRMF) (the "Company") is pleased to report the financial results for the quarter ending November 30, 2016. The Company continues to generate positive cash flow and significant year over year growth in sales of both dried flower and cannabis oils. The company is also providing an update regarding its recent voluntary recall of cannabis products, the current quantified impact to the financial statements, and some of the immediate and voluntary corrective actions and operating policies that Organigram has implemented.
Selected highlights from the quarter include the following:
Q1 - 2017 Operating Metric Q1-2016
260,291 Grams Sold (Dried Bud) 142,790
$2,230,671 Net Sales $1,029,376
65% Gross Margin % (excluding FV adjustment) 1 55%
($755,547) Net Profit ($201,211)
$272,839 Adjusted EBITDA2 (excluding FV adjustment) ($62,072)
$510,015 Cash Flow3 $25,844
1. Gross Margin% (excluding FV adjustment) is defined as net sales less costs of goods sold and indirect production costs, divided by net sales.
2. Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. It is defined as net profit before interest, income tax, depreciation and amortization, and FV adjustment to bio-assets and inventory.
3. Cash flow is calculated net profit before income tax, depreciation and amortization, share-based compensation, and FV adjustment to bio-logical assets and inventory.
The Company generated over $2.23 million in sales for the quarter on 260,291 grams of dried bud and 77,200 ml of cannabis oil sold. After adjusting for the change in fair value of inventory and biological assets, gross margin for the quarter was more than 65% and the Company generated adjusted EBITDA of $272,839 and cash flow of $510,015.
In connection to the product recalls in December 2016 and January 2017, Organigram has communicated extensively with its customers, regulators, and licensed labs regarding the issue and origin of the ingredients. The Company has taken immediate and comprehensive corrective measures within its operating and quality assurance procedures to ensure such an event does not re-occur.
"Organigram, like many of the first movers in this emerging industry, has experienced incredible growth in our business, operating infrastructure, and within our team. We have also faced challenges and setbacks as the regulations that govern our industry and the market in which we operate continues to evolve. Thanks to the prompt action of our team, the understanding and loyalty of our patients and investors, the support of our licensed testing counterparties, and the collaboration and oversight of our industry's regulators, the Company has been able to address these challenges and setbacks immediately and definitively," says Denis Arsenault, Chief Executive Officer of Organigram.
Organigram is working closely with Health Canada to determine the origin of the non-permitted ingredients. Since the voluntary product recall, Organigram has successfully harvested and tested new batches of organic as well as non-organic medical cannabis and has maintained inventory in its online store to ensure Organigram patients do not go without medication.
As a result of the recall, the unrealized fair value adjustment of inventory includes a loss of $499,857 for the three-month period ended November 30, 2016 and there may be further adjustments to the unrealized fair value of biological assets and inventory.
"This process, the required action and disclosure, combined with the necessity for each producer to track every product in the regulated cannabis market highlights that the Canadian cannabis regulatory system works, that Canadian consumers are being protected, and that the regulations governing the cannabis market in Canada provide a gold standard for the world to follow", says Arsenault.
The Company has seen great progress with its onsite expansion initiatives, and is pleased to share additional details relating to the phase 3 expansion, which is now expected to be completed and operational by December. The expansion infrastructure, which will be built and operated in accordance with the Company's recently supplemented quality assurance and operating procedures, is expected to increase the Company's run-rate production capacity to 17,000 kg per year by the early 2018.
"Our onsite expansion project positions Organigram to have one of the highest production levels in the industry at a time when we anticipate a very significant increase in consumer demand associated with recreational legalization. There are no additional licenses required, there is no additional capital required for the expansion, and we don't have additional locations to manage. Our business remains well capitalized, our expansion initiatives are ongoing, and our optimism about the future for Organigram remains absolute," says Larry Rogers, Chief Operating Officer.
For more information, visit www.organigram.ca
Edge, what don't you understand?
FYVeritas Pharma Advances Fifth of Six Equal Payments to Cannevert Therapeutics Ltd.
Accesswire AccesswireJanuary 23, 2017
VANCOUVER, BC / ACCESSWIRE / January 23, 2017 / Veritas Pharma Inc. (CNSX:VRT) (OTC PINK: VRTHF) (2VP.F), an emerging discovery and IP development company, is pleased to announce that it has completed its second to last payment of $250,000 to Cannevert Therapeutics Ltd. (CTL). This latest installment brings Veritas' total investment in CTL to $1,250,000. An additional $250,000 needs to be paid by May 1st, 2017. The final payment will grant Veritas Pharma an 80% ownership interest in CTL, with an option to purchase the remaining 20%.
Cannevert has effectively been acting as the research arm of Veritas, as it currently has an exclusive license agreement to market all proprietary products developed by them. Additionally, all monetary advances made thus far have been used to expand CTL's R&D efforts. With the latest payment, CTL will provide Veritas with a report on its current research program. We anticipate to have it within the next 10 days, at which point the principal results will be announced.
Dr. Lui Franciosi, Veritas' CEO, stated "Cannevert team is composed of a veteran scientific team whom have previously developed successful pharmaceutical drugs and have created over a billion dollars in shareholder value along the way. I believe that our latest payment to Cannevert has solidified our commitment to each other and secures our continued collaboration. I would also like to extend my thanks to those who participated in the last financing, in particular Marapharm Ventures Inc., as it has enabled Veritas to bring this this transaction to the cusp of completion."
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. All payments made by Veritas to date have been used to expand CTL's R&D efforts and this funding has partially been matched by research grants.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
SOURCE: Veritas Pharma Inc.
I
Veritas Pharma Advances Fifth of Six Equal Payments to Cannevert Therapeutics Ltd.
Accesswire AccesswireJanuary 23, 2017
VANCOUVER, BC / ACCESSWIRE / January 23, 2017 / Veritas Pharma Inc. (CNSX:VRT) (OTC PINK: VRTHF) (2VP.F), an emerging discovery and IP development company, is pleased to announce that it has completed its second to last payment of $250,000 to Cannevert Therapeutics Ltd. (CTL). This latest installment brings Veritas' total investment in CTL to $1,250,000. An additional $250,000 needs to be paid by May 1st, 2017. The final payment will grant Veritas Pharma an 80% ownership interest in CTL, with an option to purchase the remaining 20%.
Cannevert has effectively been acting as the research arm of Veritas, as it currently has an exclusive license agreement to market all proprietary products developed by them. Additionally, all monetary advances made thus far have been used to expand CTL's R&D efforts. With the latest payment, CTL will provide Veritas with a report on its current research program. We anticipate to have it within the next 10 days, at which point the principal results will be announced.
Dr. Lui Franciosi, Veritas' CEO, stated "Cannevert team is composed of a veteran scientific team whom have previously developed successful pharmaceutical drugs and have created over a billion dollars in shareholder value along the way. I believe that our latest payment to Cannevert has solidified our commitment to each other and secures our continued collaboration. I would also like to extend my thanks to those who participated in the last financing, in particular Marapharm Ventures Inc., as it has enabled Veritas to bring this this transaction to the cusp of completion."
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. All payments made by Veritas to date have been used to expand CTL's R&D efforts and this funding has partially been matched by research grants.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
SOURCE: Veritas Pharma Inc.
How come Mettrum isn't trading?
FYCanopy Growth Corp (TSX:CGC) (NASDAQOTH:TWMJF) and Aphria, Inc. (NASDAQOTH:APHQF) are two Canadian companies worthy of consideration; however, both companies are investing heavily in their businesses, and thus, could have uneven profit growth over the coming years. They're also richly valued by investors already.
For example, Canopy Growth is a leader in Canada's medical marijuana market, and it has inked a marketing deal with marijuana icon Snoop Dog that could help accelerate sales. But, revenue remains less than $10 million per quarter, and its market cap is already near $1 billion.
Aphria's story is similar. The company's knee-deep in expanding production, but it only earned $0.01 Canadian per share last quarter on just CA$4.4 million in sales. Yet, it's being valued at roughly a half billion dollars.
I. Yahoo Finance morning news!
FYI. On Yahoo finance Morning news!
Canopy Growth Corp (TSX:CGC) (NASDAQOTH:TWMJF) and Aphria, Inc. (NASDAQOTH:APHQF) are two Canadian companies worthy of consideration; however, both companies are investing heavily in their businesses, and thus, could have uneven profit growth over the coming years. They're also richly valued by investors already.
For example, Canopy Growth is a leader in Canada's medical marijuana market, and it has inked a marketing deal with marijuana icon Snoop Dog that could help accelerate sales. But, revenue remains less than $10 million per quarter, and its market cap is already near $1 billion.
Aphria's story is similar. The company's knee-deep in expanding production, but it only earned $0.01 Canadian per share last quarter on just CA$4.4 million in sales. Yet, it's being valued at roughly a half billion dollars.
What price were you able to buy in at? I bet we see .50 by Tues.
If you want a detailed description of this company go to Yahoo Finance and
enter PRMCF and look in the summary on the left side for the definition of
their purpose.
Cronos Group, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada?s Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group was incorporated in January, 2013 and is based in Toronto, Canada.